Clinical Trial Update: Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for rectal indomethacin aimed at preventing post-ERCP pancreatitis (Phase 2 and Phase 3) with completed status and results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-ercp Pancreatitis

Drugs mentioned

• Rectal Indomethacin (indomethacin)

Snippet

Sponsor: Indiana University | Conditions: Post-ERCP Pancreatitis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2019-06-18